Current Opinion in Molecular Therapeutics

Log on / register
Feedback | Support | My details

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

Quick Search

	Current Opinion in Molecular Therapeutics
	BioMed Central
	PubMed Central
	PubMed

Jump to article


vol.	page no.

Current Opinion in Molecular Therapeutics

Advanced search

Archive

Current Opinion journals

About this journal

Current Opinion in Molecular Therapeutics, Volume 5, Issue 1 (February 2003)

Current Opinion in Molecular Therapeutics is published bimonthly and covers the broad field of molecular medicine, including viral and non-viral gene therapy, oligonucleotides, peptide therapeutics, antibody approaches, molecular vaccines, and the technologies underlying genomics and proteomics.

Access to the full text or PDF of articles from Current Opinion in Molecular Therapeutics requires a subscription to the journal. Individual PDFs may be purchased by contacting ts.ids@thomson.com.

previous issue

Paper alert
M Read, H Yu
Current Opinion in Molecular Therapeutics 2003, 5:1-3 (18

February

2003)
[Abstract] [Full text] [PDF]

Patent alert
D Banerjee
Current Opinion in Molecular Therapeutics 2003, 5:4-5 (18

February

2003)
[Abstract] [Full text] [PDF]

Molecular, viral and cell-based vaccines for disease prevention and therapy
S Brown
Current Opinion in Molecular Therapeutics 2003, 5:6-7 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

A need for effective adjuvants
CJ Bunce, MA Morse
Current Opinion in Molecular Therapeutics 2003, 5:8-9 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Live attenuated bacteria as vectors to deliver plasmid DNA vaccines
G Dietrich, S Spreng, D Favre, J-F Viret, CA Guzman
Current Opinion in Molecular Therapeutics 2003, 5:10-19 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Improving DNA vaccine potency via modification of professional antigen presenting cells
C-F Hung, TC Wu
Current Opinion in Molecular Therapeutics 2003, 5:20-24 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

Development of prophylactic AIDS vaccines: The current state of affairs
T Hanke
Current Opinion in Molecular Therapeutics 2003, 5:25-32 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

Recent developments in vaccines to prevent meningococcal serogroup B infections
CL Vermont, GPJM Dobbelsteen, groot R de
Current Opinion in Molecular Therapeutics 2003, 5:33-38 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Proteomics for monitoring immune responses to cancer vaccines
PJ Mosca, HK Lyerly, CD Ching, AC Hobeika, TM Clay, MA Morse
Current Opinion in Molecular Therapeutics 2003, 5:39-43 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Recombinant toxins for the treatment of cancer
RJ Kreitman
Current Opinion in Molecular Therapeutics 2003, 5:44-51 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

Anti-interferon-gamma antibodies in the treatment of autoimmune diseases
B Skurkovich, S Skurkovich
Current Opinion in Molecular Therapeutics 2003, 5:52-57 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Development of vaccines to help treat drug dependence
CJ Bunce, PT Loudon, C Akers, J Dobson, DM Wood
Current Opinion in Molecular Therapeutics 2003, 5:58-63 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Technology evaluation: MRA, Chugai
C Ding, G Jones
Current Opinion in Molecular Therapeutics 2003, 5:64-69 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research
RH Kennett
Current Opinion in Molecular Therapeutics 2003, 5:70-75 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Technology evaluation: ISIS-104838, OraSense
P Kennewell
Current Opinion in Molecular Therapeutics 2003, 5:76-80 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

Technology evaluation: Omalizumab, Genentech/Novartis/Tanox
AL Lazaar
Current Opinion in Molecular Therapeutics 2003, 5:81-89 (18

February

2003)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]

previous issue

Current Opinion in Molecular Therapeutics Volumes

Volume 11 (2009)

Volume 10 (2008)

Volume 9 (2007)

Volume 8 (2006)

Volume 7 (2005)

Volume 6 (2004)

Volume 5 (2003)

Volume 4 (2002)

Volume 3 (2001)

Volume 2 (2000)

Volume 1 (1999)

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us

© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.